InvestSMART

Genetic Signatures Limited (ASX:GSS)

ALERT: Price-sensitive ASX Announcement for GSS
Current share price for GSS : $0.058 -0.162 (-73.64%)+
Announcement
Release
20 Jan 2026 8:20AM
Price at Release
$0.220
Full Release
download
Summary
Genetic Signatures Limited reported its Appendix 4C Quarterly Activities and Cash Flow Report for the quarter ending 31 December 2025. The company recorded sales of $3.3 million for Q2 FY26, with revenue contributions from Australia, EMEA, and the US. The company emphasized the implementation of its EasyScreen™ Gastrointestinal Parasite Detection Kit in the US, alongside ongoing evaluations in the EMEA region. It received $4.4 million from the Australian Research & Development Tax Incentive and reported a strong cash position of $29.7 million. The company continues to pursue growth in international markets and development of automated diagnostic solutions.
Key Points
  • Sales of $3.3 million for Q2 FY26
  • Revenue contributions from Australia, EMEA, and the US
  • Implementation of EasyScreen™ Gastrointestinal Parasite Detection Kit in the US
  • Received $4.4 million from the Australian Research & Development Tax Incentive
  • Total cash balance of $29.7 million as of 31 December 2025
  • Focus on international market growth and development of automated diagnostic solutions
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.